{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:59:39Z","timestamp":1780984779468,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10067-026-08144-5","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:35:26Z","timestamp":1777102526000},"page":"3399-3404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the phenotypic expression of HLA-B27 in psoriatic arthritis"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6822-6730","authenticated-orcid":false,"given":"Cristina","family":"Macia-Villa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9148-671X","authenticated-orcid":false,"given":"Jose Ignacio","family":"Fernandez-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4941-594X","authenticated-orcid":false,"given":"Mauro","family":"Ferre-Sanfrancisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5147-385X","authenticated-orcid":false,"given":"Daniel Albert","family":"Mendoza-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4645-1781","authenticated-orcid":false,"given":"Ana Maria","family":"Ruiz-Bejerano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9574-8449","authenticated-orcid":false,"given":"Celia","family":"Ferrez-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1776-9142","authenticated-orcid":false,"given":"Jose Luis","family":"Morell-Hita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"8144_CR1","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s12325-023-02475-4","volume":"40","author":"A Kavanaugh","year":"2023","unstructured":"Kavanaugh A, Baraliakos X, Gao S et al (2023) Genetic and molecular distinctions between axial psoriatic arthritis and radiographic axial spondyloarthritis: post hoc analyses from four phase 3 clinical trials. Adv Ther 40:2439\u20132456. https:\/\/doi.org\/10.1007\/s12325-023-02475-4","journal-title":"Adv Ther"},{"key":"8144_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/rheumatology\/kev296","volume":"55","author":"R Queiro","year":"2016","unstructured":"Queiro R, Morante I, Cabezas I, Acasuso B (2016) HLA-B27 and psoriatic disease: a modern view of an old relationship. Rheumatology Oxford 55:221\u2013229. https:\/\/doi.org\/10.1093\/rheumatology\/kev296","journal-title":"Rheumatology Oxford"},{"key":"8144_CR3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.55563\/clinexprheumatol\/aiams5","volume":"39","author":"P Nikamo","year":"2021","unstructured":"Nikamo P, Gudbjornsson B, Laasonen L et al (2021) HLA-B*27 is significantly enriched in Nordic patients with psoriatic arthritis mutilans. Clin Exp Rheumatol 39:775\u2013780","journal-title":"Clin Exp Rheumatol"},{"key":"8144_CR4","first-page":"586","volume":"13","author":"DD Gladman","year":"1986","unstructured":"Gladman DD, Anhorn KA, Schachter RK, Mervart H (1986) HLA antigens in psoriatic arthritis. J Rheumatol 13:586\u2013592","journal-title":"J Rheumatol"},{"key":"8144_CR5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/art.40423","volume":"70","author":"A Polachek","year":"2018","unstructured":"Polachek A, Cook R, Chandran V et al (2018) The association between HLA genetic susceptibility markers and sonographic enthesitis in Psoriatic Arthritis. Arthritis Rheumatol 70:756\u2013762. https:\/\/doi.org\/10.1002\/art.40423","journal-title":"Arthritis Rheumatol"},{"key":"8144_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/jpm14070716","volume":"14","author":"E Bellis","year":"2024","unstructured":"Bellis E, Ruscitti P, Donzella D et al (2024) Retention rate of ixekizumab in psoriatic arthritis: a real-world study. J Pers Med 14:716. https:\/\/doi.org\/10.3390\/jpm14070716","journal-title":"J Pers Med"},{"key":"8144_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.55563\/clinexprheumatol\/pqpzef","volume":"43","author":"G Alp","year":"2025","unstructured":"Alp G, Kara M, Cinakli H (2025) Potential difficult-to-treat psoriatic arthritis real-world prevalence and contributing factors. Clin Exp Rheumatol 43:41\u201347. https:\/\/doi.org\/10.55563\/clinexprheumatol\/pqpzef","journal-title":"Clin Exp Rheumatol"},{"key":"8144_CR8","doi-asserted-by":"publisher","first-page":"e002696","DOI":"10.1136\/rmdopen-2022-002696","volume":"8","author":"M Arevalo Salaet","year":"2022","unstructured":"Arevalo Salaet M, L\u00f3pez-Medina C, Moreno M et al (2022) Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study. RMD Open 8:e002696. https:\/\/doi.org\/10.1136\/rmdopen-2022-002696","journal-title":"RMD Open"},{"key":"8144_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1590\/s0365-05962012000600004","volume":"87","author":"DG Ruiz","year":"2012","unstructured":"Ruiz DG, de Azevedo MNL, Lupi O (2012) HLA-B27 frequency in a group of patients with psoriatic arthritis. An Bras Dermatol 87:847\u2013850. https:\/\/doi.org\/10.1590\/s0365-05962012000600004","journal-title":"An Bras Dermatol"},{"issue":"25","key":"8144_CR10","doi-asserted-by":"publisher","first-page":"04433","DOI":"10.1016\/j.ard.2025.10.002","volume":"S0003\u20134967","author":"H Marzo-Ortega","year":"2025","unstructured":"Marzo-Ortega H, Harrison SR, Fragoulis GE et al (2025) EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis. Ann Rheum Dis S0003\u20134967(25):04433\u201304434. https:\/\/doi.org\/10.1016\/j.ard.2025.10.002","journal-title":"Ann Rheum Dis"},{"key":"8144_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/acr2.11416","volume":"4","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Chakravarty SD, McLean RR et al (2022) treatment responses in patients with psoriatic arthritis axial disease according to human leukocyte antigen-B27 status: an analysis from the corevitas psoriatic arthritis\/spondyloarthritis registry. ACR Open Rheumatol 4:447\u2013456. https:\/\/doi.org\/10.1002\/acr2.11416","journal-title":"ACR Open Rheumatol"},{"key":"8144_CR12","doi-asserted-by":"publisher","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","volume":"3","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Helliwell PS, Gladman DD et al (2021) Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol 3:e715\u2013e723. https:\/\/doi.org\/10.1016\/S2665-9913(21)00105-3","journal-title":"Lancet Rheumatol"},{"key":"8144_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003235","volume":"9","author":"M\u00c1 Puche-Larrubia","year":"2023","unstructured":"Puche-Larrubia M\u00c1, Ladehesa-Pineda L, V\u00e1zquez-Mellado J et al (2023) Identification of the first signs or symptoms in different spondyloarthritis subtypes and their association with HLA-B27: data from REGISPONSER and RESPONDIA registries. RMD Open 9:e003235. https:\/\/doi.org\/10.1136\/rmdopen-2023-003235","journal-title":"RMD Open"},{"key":"8144_CR14","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/art.38050","volume":"65","author":"C Castillo-Gallego","year":"2013","unstructured":"Castillo-Gallego C, Aydin SZ, Emery P et al (2013) Magnetic resonance imaging assessment of axial psoriatic arthritis: extent of disease relates to HLA-B27. Arthritis Rheum 65:2274\u20132278. https:\/\/doi.org\/10.1002\/art.38050","journal-title":"Arthritis Rheum"},{"key":"8144_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1053\/sarh.2002.33470","volume":"31","author":"R Queiro","year":"2002","unstructured":"Queiro R, Sarasqueta C, Belzunegui J et al (2002) Psoriatic spondyloarthropathy: a comparative study between HLA-B27 positive and HLA-B27 negative disease. Semin Arthritis Rheum 31:413\u2013418. https:\/\/doi.org\/10.1053\/sarh.2002.33470","journal-title":"Semin Arthritis Rheum"},{"key":"8144_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152823","author":"SD Donato","year":"2025","unstructured":"Donato SD, Smerilli G, Becciolini A et al (2025) Entheseal structural damage according to OMERACT definitions unveils distinct ultrasound phenotypes in SpA: findings from the DEUS multicentre study. Semin Arthritis Rheum. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152823","journal-title":"Semin Arthritis Rheum"},{"key":"8144_CR17","first-page":"505","volume":"30","author":"R Queiro","year":"2003","unstructured":"Queiro R, Torre JC, Gonz\u00e1lez S et al (2003) HLA antigens may influence the age of onset of psoriasis and psoriatic arthritis. J Rheumatol 30:505\u2013507","journal-title":"J Rheumatol"},{"key":"8144_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290632","volume":"19","author":"NC Chavez-Tapia","year":"2024","unstructured":"Chavez-Tapia NC, Sanchez-Jimenez BA, Vida\u00f1a-Perez D et al (2024) Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: a multicenter cross sectional-study. PLoS ONE 19:e0290632. https:\/\/doi.org\/10.1371\/journal.pone.0290632","journal-title":"PLoS ONE"},{"key":"8144_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jbspin.2020.03.012","volume":"87","author":"M Ar\u00e9valo","year":"2020","unstructured":"Ar\u00e9valo M, L\u00f3pez-Medina C, Moreno Martinez-Losa M et al (2020) Role of HLA-B27 in the comorbidities observed in Axial Spondyloarthritis: data from COMOSPA. Joint Bone Spine 87:445\u2013448. https:\/\/doi.org\/10.1016\/j.jbspin.2020.03.012","journal-title":"Joint Bone Spine"},{"key":"8144_CR20","doi-asserted-by":"publisher","first-page":"e16704","DOI":"10.1097\/MD.0000000000016704","volume":"98","author":"A Karrar","year":"2019","unstructured":"Karrar A, Hariharan S, Fazel Y et al (2019) Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease. Medicine (Baltimore) 98:e16704. https:\/\/doi.org\/10.1097\/MD.0000000000016704","journal-title":"Medicine (Baltimore)"},{"key":"8144_CR21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.55563\/clinexprheumatol\/anuuqb","volume":"41","author":"C Mac\u00eda-Villa","year":"2023","unstructured":"Mac\u00eda-Villa C, Morell-Hita JL, Revenga-Mart\u00ednez M, D\u00edaz-Miguel P\u00e9rez C (2023) HLA-Cw6 allele and biologic therapy are protective factors against liver fibrosis in psoriatic arthritis patients. Clin Exp Rheumatol 41:1179\u20131182. https:\/\/doi.org\/10.55563\/clinexprheumatol\/anuuqb","journal-title":"Clin Exp Rheumatol"},{"key":"8144_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13075-023-03045-3","volume":"25","author":"M Valero","year":"2023","unstructured":"Valero M, S\u00e1nchez-Piedra C, Freire M et al (2023) Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry. Arthritis Res Ther 25:86. https:\/\/doi.org\/10.1186\/s13075-023-03045-3","journal-title":"Arthritis Res Ther"},{"key":"8144_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002303","volume":"8","author":"X Baraliakos","year":"2022","unstructured":"Baraliakos X, Pournara E, Gossec L et al (2022) Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial. RMD Open 8:e002303. https:\/\/doi.org\/10.1136\/rmdopen-2022-002303","journal-title":"RMD Open"},{"key":"8144_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-023-00295-2","volume":"63","author":"F Molica Colella","year":"2023","unstructured":"Molica Colella F, Zizzo G, Parrino V et al (2023) Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort. Adv Rheumatol 63:15. https:\/\/doi.org\/10.1186\/s42358-023-00295-2","journal-title":"Adv Rheumatol"},{"key":"8144_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001149","volume":"6","author":"PS Helliwell","year":"2020","unstructured":"Helliwell PS, Gladman DD, Chakravarty SD et al (2020) Effects of ustekinumab on spondylitis-associated endpoints in TNFi-na\u00efve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. RMD Open 6:e001149. https:\/\/doi.org\/10.1136\/rmdopen-2019-001149","journal-title":"RMD Open"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08144-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08144-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08144-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:25:59Z","timestamp":1780982759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08144-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8144"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08144-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}